Correlation between observed disease activities, DAS28 scores and trough levels of infliximab and adalimumab over time
| Clinical response | Infliximab (n = 35) | Adalimumab (n = 34) | |||||||
| Baseline | 3 months | 6 months | Baseline | 3 months | 6 months | ||||
| Number (%) of patients | |||||||||
| Good | – | 11 (31) | 15 (43) | – | 17 (50) | 16 (47) | |||
| Moderate | – | 9 (26) | 6 (17) | – | 7 (21) | 8 (24) | |||
| None | – | 15 (43) | 14 (40) | – | 10 (29) | 10 (29) | |||
| DAS28, mean (SD) | |||||||||
| Good | 5.5 (0.9) | 2.9 (0.7) | 2.7 (0.8) | 5.7 (0.9) | 3.0 (0.6) | 2.7 (0.6) | |||
| Moderate | 7.0 (1.0) | 4.9 (1.3) | 4.5 (1.0) | 6.0 (1.3) | 3.6 (1.1) | 3.7 (0.8) | |||
| None | 5.2 (1.2) | 4.7 (1.4) | 5.4 (0.8) | 5.6 (1.0) | 4.9 (1.0) | 4.9 (0.5) | |||
| Serum trough levels of drug (μg/ml), mean (range) | |||||||||
| Good | <0.2 | 3.1 (0.8–17) | 2.7 (0.9–10) | <0.2 | 31 (3–151) | 32 (3–150) | |||
| Moderate | <0.2 | 1.9 (0–5) | 0.8 (0–9) | <0.2 | 12 (7–138) | 14 (2–41) | |||
| None | <0.2 | 0.2 (0–14) | 0 (0–0) | <0.2 | 2 (0–7) | 1 (0–0) | |||
Clinical responses were recorded using the EULAR response criteria.
DAS28, 28-joint count Disease Activity Score.